315 related articles for article (PubMed ID: 37720221)
1. The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies.
Xu J; Shi Q; Wang B; Ji T; Guo W; Ren T; Tang X
Front Immunol; 2023; 14():1257254. PubMed ID: 37720221
[TBL] [Abstract][Full Text] [Related]
2. Complex immune microenvironment of chordoma: a road map for future treatment.
Niu HQ; Zheng BY; Zou MX; Zheng BW
J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908855
[TBL] [Abstract][Full Text] [Related]
3. The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol.
Banu MA; Raza SM; Amini M; Seaman S; Rubino F; Snyder R; Patel S; DeMonte F; Conley AP
Neurosurg Focus; 2024 May; 56(5):E15. PubMed ID: 38691867
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy as a Potential Treatment for Chordoma: a Review.
Patel SS; Schwab JH
Curr Oncol Rep; 2016 Sep; 18(9):55. PubMed ID: 27475804
[TBL] [Abstract][Full Text] [Related]
5. Multimodal profiling of chordoma immunity reveals distinct immune contextures.
van Oost S; Meijer DM; Ijsselsteijn ME; Roelands JP; van den Akker BEMW; van der Breggen R; Briaire-de Bruijn IH; van der Ploeg M; Wijers-Koster PM; Polak SB; Peul WC; van der Wal RJP; de Miranda NFCC; Bovee JVMG
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272563
[TBL] [Abstract][Full Text] [Related]
6. Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors.
Shinojima N; Ozono K; Yamamoto H; Abe S; Sasaki R; Tomita Y; Kai A; Mori R; Yamamoto T; Uekawa K; Matsui H; Nosaka K; Matsuzaki H; Komohara Y; Mikami Y; Mukasa A
Brain Tumor Pathol; 2023 Jul; 40(3):185-190. PubMed ID: 37086325
[TBL] [Abstract][Full Text] [Related]
7. Chordoma.
Ulici V; Hart J
Arch Pathol Lab Med; 2022 Mar; 146(3):386-395. PubMed ID: 34319396
[TBL] [Abstract][Full Text] [Related]
8. Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression.
Xu J; Shi Q; Lou J; Wang B; Wang W; Niu J; Guo L; Chen C; Yu Y; Huang Y; Guo W; Lan J; Zhu Y; Ren T; Tang X
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37185233
[TBL] [Abstract][Full Text] [Related]
9. Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies.
Lopez DC; Robbins YL; Kowalczyk JT; Lassoued W; Gulley JL; Miettinen MM; Gallia GL; Allen CT; Hodge JW; London NR
Front Oncol; 2022; 12():1012058. PubMed ID: 36338744
[TBL] [Abstract][Full Text] [Related]
10. The role and participation of immune cells in the endometrial tumor microenvironment.
Dey DK; Krause D; Rai R; Choudhary S; Dockery LE; Chandra V
Pharmacol Ther; 2023 Nov; 251():108526. PubMed ID: 37690483
[TBL] [Abstract][Full Text] [Related]
11. Tumor microenvironment and immunotherapy of oral cancer.
Liu C; Wang M; Zhang H; Li C; Zhang T; Liu H; Zhu S; Chen J
Eur J Med Res; 2022 Oct; 27(1):198. PubMed ID: 36209263
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of Pyroptosis-Related Genes and Tumor Microenvironment Infiltration Characterization in Breast Cancer.
Wu J; Zhu Y; Luo M; Li L
Front Immunol; 2021; 12():748221. PubMed ID: 34659246
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells.
Hoke ATK; Padget MR; Fabian KP; Nandal A; Gallia GL; Bilusic M; Soon-Shiong P; Hodge JW; London NR
Cancer Res Commun; 2021 Dec; 1(3):127-139. PubMed ID: 35765577
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.
Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G
Front Immunol; 2022; 13():961796. PubMed ID: 35911673
[TBL] [Abstract][Full Text] [Related]
16. Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy.
Gounder MM; Zhu G; Roshal L; Lis E; Daigle SR; Blakemore SJ; Michaud NR; Hameed M; Hollmann TJ
Clin Cancer Res; 2019 Apr; 25(7):2064-2071. PubMed ID: 30642912
[TBL] [Abstract][Full Text] [Related]
17. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy as a Promising Option for the Treatment of Advanced Chordoma: A Systemic Review.
Wang X; Chen Z; Li B; Fan J; Xu W; Xiao J
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612259
[TBL] [Abstract][Full Text] [Related]
20. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
